Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Lilly to Expand Japan Business via Alliances with Subsidiaries in Other Asian Countries
May 2, 2011
- Mitsui to Acquire Mercian's Pharma and Chemicals Business
May 2, 2011
- Drug Price Listings to Be Delayed One Month: Korosho
May 2, 2011
- OECD Japan Report Calls For Restraint in Social Security Spending
May 2, 2011
- JMA to Propose Postponing Revision of Medical, Nursing Fees
May 2, 2011
- Xyzal Ranked No. 1 in GP Market in February: RepTrack Survey
May 2, 2011
- Members of JMA Board of Trustees Disagree on Resolution to Postpone Revisions
May 2, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
May 2, 2011
- Nat'l Consensus Needed on Drugs' Cost-effectiveness Assessment: Prof. Endo
May 2, 2011
- Wakamoto's Mid-term Management Plan Calls For Return to Black in FY2011
May 2, 2011
- Korosho to Introduce Relief Program for Families of Patients Who Die due to Anticancer Drug-related Adverse Effects
May 2, 2011
- Meiji Seika Pharma Aims at Sales of ¥200 Bil. in FY2020
May 2, 2011
- Wakamoto to Set Up JV for Generics with Taiwan Drugmaker
May 2, 2011
- HSC Approves Draft Report on Measures against Rheumatism
May 2, 2011
- Moratorium on Copayment by Quake Victims to Be Extended: Korosho
May 2, 2011
- Kyowa Kirin Completes Legal Procedures for Acquisition of ProStrakan
May 2, 2011
- Chugai's Pegasys Granted Priority Review Status for CHB
May 2, 2011
- Outgoing KEIZAI DOYUKAI Chairman Expresses Hope for His Successor from Regulation-bound Industry
May 2, 2011
- Kaken to Achieve Its Operating Profits Goal: Mizuho Securities
May 2, 2011
- Gov't Designates Eribulin as Ad-restricted Drug
May 2, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…